US regulatory status: approved.
biotech · Fabry Disease · Bioequivalence · PLX
Protalix Biotherapeutics
Protalix BioTherapeutics
Protalix Biotherapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA HQ
1994 Founded
197 Employees
Public company Type
PLX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2 Snunit St., Science Park, POB 455, Carmiel, 2161401, IL, HACKENSACK, NJ, USA
- Founded
- 1994
- Employees
- 197
- Programs
- 21
- Drugs
- 14
- Patents
- 22
Protalix Biotherapeutics pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Protalix Biotherapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Protalix Biotherapeutics in public FDA and regional records.
-
Development asset linked to Protalix Biotherapeutics in public FDA and regional records.
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Protalix Biotherapeutics's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Protalix Biotherapeutics's portfolio.
-
ibuprofen
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
pegunigalsidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Protalix Biotherapeutics's portfolio. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
Development asset linked to Protalix Biotherapeutics in public FDA and regional records.
-
Development asset linked to Protalix Biotherapeutics in public FDA and regional records.